December 2020
BJC Staff
The patients who developed cardiotoxicity were treated with beta blockers (carvedilol), angiotensin-converting enzyme inhibitors (enalapril) or angiotensin receptor blockers (valsartan), aldosterone antagonists (eplerenone), digitalis and diuretics (furosemide), as needed. When patients remained symptomatic and met the PARADIGM-HF inclusion criteria, sacubitril/valsartan was started instead of enalapril or valsartan. Results showed that sacubitril/valsartan therapy produced an improvement in ventricular remodelling, diastolic dysfunction, and on symptoms, reflected in the New York Heart Association class and the six-minute walk test. The auth
January 2018 doi:10.5837/bjc.2018.002 Online First
Alison Carr, Fosca De Iorio, Martin R Cowie
Introduction Acute heart failure (AHF) syndromes are the leading cause of hospitalisation in patients over 65 years of age in the UK, accounting for 67,000 admissions per year.1 The immediate management of AHF focuses on symptom relief and stabilisation of the patient’s haemodynamic profile – traditionally achieved with a combination of oxygen, diuretics and nitrate therapy.1-5 Recent guidelines from the National Institute for Health and Care Excellence (NICE),1 and the European Society of Cardiology (ESC),5 have highlighted the poor-quality evidence base for many of these interventions.3,4,6 The ESC guidelines (updated in 2016) state th
October 2015 Br J Cardiol 2015;22:138–142 Online First
BJCardio Staff
(more…)
March 2013 Br J Cardiol 2013;20(suppl 1): S1–S16 doi:10.5837/bjc.2013.s01
Dr Terry McCormack, Dr Chris Arden, Dr Alan Begg, Professor Mark Caulfield, Dr Kathryn Griffith, Ms Helen Williams
(more…)
March 2010 Br J Cardiol 2010;17:69-70
Optimising care UK hospitals should set up acute heart failure units to help raise standards of care, according to Professor Henry Dargie (Golden Jubilee National Hospital, Glasgow). Presenting the inaugural Philip Poole-Wilson memorial lecture (see box), Professor Dargie said that there have been great improvements in heart failure treatment, with effective drugs, devices and interventions, plus a multidisciplinary team approach. In addition, clinical trials have shown a 50% absolute reduction in heart failure mortality with modern treatments, proving what can be achieved with specialist care. But trial results are not being reproduced in c
September 2002 Br J Cardiol 2002;9:481-7
Mike Mead
No content available
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits